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A
Aboriginal renal failure (abst) 1274
Acetate dialysis, compared to bicarbonate (abst). . . 283, 1784
Acidification in cortical distal tubule 1543
Acidosis alters ammoniagenesis, LLC-PK1 cells 1014
Acute renal failure
atnal natriuretic peptide 1730
biopsy assessment, transplantation 44: S-65
clinical studies (abst) 284
contrast media-induced, theophylline 1425
dichromate, thyroid hormone, EGF 1622
graft rejection, steroid-resistant nephroses 1440
IGF-1, body growth, rat (abst) 1277
mixed cryoglobulinemia, interferon a2a (abst) 1790
pathophysiology 1355
tubular protection, ischemic injury, uremia 1759
Adenocarcinoma, renal 23
Adenoviral-mediated gene transfer, renal tubular cells .. 1220
Adhesion molecule expression, deoxyspergualin (abst).. 1257
Adriamycin nephropathy 525
AIDS, renal opportunistic infection (abst) 287
Albumin
excretion, DM, antihypertensive agents (abst) 1270
excretion, pregnancy (abst) 1269
glycated, diabetic nephropathy 1673
transferrin synthesis 1381
tubular catabolism, inflammatory lipid release 1697
Albuminuria
ambulatory BP, type 1 diabetes 45:S-134
enalapril, hypertensive NIDDM 45:S-150
reduction, diabetic nephropathy 45:S-145
Allografts
elderly as donors (abst) 1265
hepatitis C virus 238
mesangial IgA deposits, recurrence (abst) 1269
prednisolone withdrawal, children (abst) 1264
rejection, T cell receptor gene expression (abst) 1254
rejection, T cells in autoimmunity 44:S-50
tolerance 44:S-40
vascular thrombosis (abst) 1254
Alport syndrome
aS chain, collagen type IV 1504
anti-a3 alloantibodies, collagen type IV 721
Aluminoxamine kinetics 76
Aluminum alters Fe metabolism in Friend cells 636
Amadori glucose adducts, mesangial cell biology 475
Ambulatory blood pressure
24-hour monitoring, circadian rhythms (abst) 1791
24-hour monitoring (abst) 284
type 1 diabetes, albuminuria 45:S-134
Amino acids
ketoacids, very low protein diet 1182
pharmacology, glomerular function 417
transport systems 110
Aminoglycoside effects, urine and glycine betaine
(abst) 1256
Ammoniagenesis, renal pathways 1014
Amyloid nephropathy, Muckle-Wells syndrome (abst) ... 282
Amyloidosis, familial (abst) 287
AN69 membranes, anaphylaxis, bradykinin 1497
Analgesic nephropathy 1785
Anaphylaxis, HD with AN69 membranes, bradykinin... 1497
ANCA-positive glomerulonephritis (abst) 1790
Anemia
HD, intravenous iron (abst) 285
immunopotentiation by RBC, uremia, cytokines 224
Aneurysms, intracranial, in ADPKD 1140
Angioaccess catheter sepsis (abst) 282
Angioplasty, central venous stenoses 1177
Angiotensin converting enzyme (ACE)
dietary protein, uninephrectomy, rat 1587
in kidneys, diabetic and hypertensive rats (abst) 1268
Angiotensin converting enzyme (ACE) inhibition
Ang II antagonism, antiproteinuric effects 861
diabetic nephropathy 45:S-156, 45:S-161
glomerular function, PAN 537
glomerular function, pharmacology 417
renal abnormalities and 485
renal cystic disease (abst) 1266
Angiotensin II
antagonism, renal abnormalities 485
binding to AT1 receptors 177
bradykinin, PAN 537
NO synthesis inhibition (abst) 1255
tubulointerstitial nephritis, osteopontin 515
Angiotensin II receptor
gene regulation, ureteral obstruction 1614
glomerular, diabetic nephropathy (abst) 1276
Anti-GBM glomerulonephritis
f2 integrin molecules, neutrophil accumulation (abst) . 1256
crescentic (abst) 1260
ICAM-l, interstitial leukocytes 32
ICAM-1/LFA-1 interaction 700
T helper/suppressor cells, injury (abst) 1260
Anti-neutrophil proteinase 3 antibodies, ELISA (abst) .. 1257
Anti-platelet therapy, graft thrombosis 1477
Anti-Thy-l nephritis, tubulointerstitial injury (abst) 1272
Anti-TNF antibody, MC proliferation (abst) 1783
Antibodies
IL-6, pyelonephritis, pregnancy 571
neutrophil cytoplasm antigen (abst) 1257
Anticoagulation
continuous veno-venous hemofiltration (abst) 1784
during HD 912
hirudin, thrombin inhibition, HD 1753
oral prophylactic, nephrotic patients 578
prothrombin changes, heparin, HD (abst) 1784
Antidiuresis, cyclosporine induced 1203
Antihypertensive therapy
antiproteinuric response, GFR decline 45:S-174
microalbuminuria, essential hypertension 45:S-171
microalbuminuria, normotensive, DM (abst) 1270
Antioxidants, PAN, glomerular morphology (abst) 1271
Antiplatelet therapy, rHuEPO, hypertension 845
Antiproteinuric response, GFR decline 45:S-174
Antithymocyte globulin induction therapy (abst) 288
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Arginine vasopressin (AVP)
EGF antagonizes 1028
interaction, EGF (abst) 1262
nonpeptide orally active (abst) 1261
reduced oropharyngeal inhibition, elderly (abst) 1261
Arterial pressure, NO inhibition (abst) 1258
Artenovenous flstulae, MRI measures flow 884
Aspirin
renal function, rabbits (abst) 1785
renography 1170
AT1 receptors, Ang II binding 177
Atherosclerosis, LDL oxidation, uremia 876
Atomic absorption analysis, tubular fluid electrolytes... 1211
Atrial natnuretic factor receptor (abst) 1259
Atrial natriuretic peptide (ANP)
clinical ARF 1730
hyperosmolality, stimulated cGMP 1362
inhibits Na/H antiporter, VSMC 66
proximal tubular intracellular electrolytes (abst) 1260
Autoimmunity
allograft rejection 44:S-50
glomerular injury, T cell activation 44:S-8
Autosomal dominant polycystic kidney disease
(ADPKD)
anticipation, evidence for 1153
intracranial aneurysms 1140
renal ammonia 1744
Autosomal dominant primary hyperoxaluna (abst) 1782
Avascular osteonecrosis, transplantation (abst) 290
Azathioprine (abst) 1264
Azobenzenearsonate induced acute nephritis 1044
B
p2 microglobulin, vesico-uretenc reflux (abst) 1273
Balkan endemic nephropathy 1680
Bartter's syndrome, mental development (abst) 290
f2 integrin, neutrophil accumulation, anti-GBM GN
(abst) 1256
Bicarbonate dialysis, compared to acetate (abst).. . 283, 1784
Bilateral ureteral obstruction 1346
Biliary excretion, aluminoxamine/ferrioxamine 76
Biochemical markers of bone disease, children 253
Bioimpedance, circulatory evaluation (abst) 1788
Bioincompatibility perspectives 1993, 44:S-77
Biopsy
cell proliferation, post-transplant (abst) 285
estimating glomerular number, MRI and 1668
macroscopic hematuna after (abst) 286
nephropathology diagnosis (abst) 284
pathology, implantation graft (abst) 1278
percutaneous (abst) 288
percutaneous techniques compared (abst) 1789
skin, nephropathology diagnosis (abst) 284
techniques compared (abst) 1258
Trucut needle and Biopty gun (abst) 1267
Blood flow properties, IgA nephropathy (abst) 1266
Blood pressure
ambulatory, 24-hour monitoring (abst) 284, 1791
ambulatory, type 1 diabetes, albuminuna 45:S-l34
cyclosporin induced antidiuresis 1203
pre/post-dialytic, mean interdialytic (abst) 286
rHuEPO, intracellular calcium, uremia (abst) 1268
Blood viscosity, diabetic nephropathy (abst) 1273
Blood volume measurement
evaluation with bioimpedance, HD (abst) 1788
noninvasive, HD (abst) 1262
Bone disease, renal
biochemical markers, children 253
osteocalcin as marker (abst) 1785
Bone marrow transplantation, renal transplant after .... 1791
Bone mineral density (BMD)
calcitnol, ESRD 245
calcitriol, HD (abst) 1786
BQ-l23, renal effects 131
Bradykinin, anaphylaxis, AN69 membranes 1497
Brain lesions, excessive correction of hyponatremia 193
Bronchiolitis obliterans/organizing pneumonia (abst).... 1790
Brush border membranes, urate transporters 727
C
C4 null phenotype, IgA nephropathy (abst) 1259
C9, 254 mAb detects neoepitope (abst) 1266
Ca2 +
cardiac monocytes and CRF 1113
cellular, luminal V1-receptor, collecting duct 811
protein kinases, hsp7O gene induction 1093
transport, calbindin 9K 469
transport, calbindin 28K 461
Calbindin 9K, Ca2 transport 469
Calbindin 28K, Ca2 transport 461
Calbindin D-28K, vitamin D 95
Calcitonin, endogenous, rat renal function (abst) 1255
Calcitnol
bone mineral density, ESRD 245
degradative enzymes, renal failure 509
protein intake, idiopathic calcium stones (abst) 1784
receptor regulation, mRNA, RF 1020
Calcitnol therapy
bone mineral density, HD (abst) 1786
oral, HD, children (abst) 1264
oral, IV, hyperparathyroidism, ESRD 1710
secondary hyperparathyroidism (abst) 1789
Calcium
homeostasis and the kidney 44:S-97
hypertonicity-stimulated urea transport (abst) 1254
intracellular, insulin, MC function 1318
intracellular, NaJH exchange, essential hypertension.. 1037
intracellular, rHuEPO, hypertension, uremia (abst)... 1268
oral, suppresses PTH, mild CRF (abst) 1275
renal content, hypercalciuria 58
streptomycin alters free transients (abst) 1277
Calcium antagonists, pharmacology, glomerular
function 417
Calcium nephrolithiasis, idiopathic (abst) 1782
Calcium oxalate stones, prognosis 1721
Calcium reabsorption, vitamin D3
effect of CaBP 9K 469
effect of CaBP 28K 461
Calcium renal stones
calcitnol, protein intake (abst) 1784
prognosis 1721
Cancer, renal, retinoic acid, cell growth 23
Capillary wall distension, counteraction by podocytes ... 369
Cardiac function, fractional shortening, HD (abst) 285
Cardiac monocytes, Ca2, and CRF 1113
Cardiac surgery, tubular nephrotoxicity (abst) 1274
Cardiovascular disease, smoking, transplantation (abst) . 1263
Carpal tunnel syndrome, HD (abst) 284
Catheterization, subclavian occlusion after (abst) 286
Catheters, temporary angioaccess, sepsis (abst) 282
CD45 isoforms, post-transplant (abst) 283
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Cell-mediated immune injury 1044
Central venous stenoses, PTA and vascular Walistents.. 1177
cGMP
inhibits Na/H antiporter, VSMC 66
stimulated, hyperosmolality of ANP 1362
Chelators, mucormycosis, deferoxamine therapy 667
Children
catch-up growth, renal tubular acidosis (abst) 1782
chronic renal failure (abst) 290
diabetes, juxtaglomerular body abnormalities 1132
growth hormone, dietary therapy, CRF (abst) 1273
high dose oral calcitriol, HD (abst) 1264
lupus nephritis, cyclophosphamide therapy (abst) 289
osteodystrophy biochemical markers 253
prednisolone withdrawal (abst) 1264
pyelonephritis, dimercaptosuccinic acid scan (abst)... 1790
transplantation (abst) 282, 290, 1264
urolithiasis (abst) 1790
vesico-ureteric reflux (abst) 1273
Chinese herbs nephropathy 1680
Cholesterol synthesis inhibitors 45:S-51
Chronic ambulatory peritoneal dialysis (CAPD)
early discharge program (abst) 1259
plasma cytokines, inhibitors 890
Chronic renal failure
calcitnol, bone mineral density 245
cardiac monocytes and Ca2 1113
children (abst) 290
cytokine autoantibodies 1484
decreased LDL clearance, uremia 561
glycine betaine, sorbitol, DM (abst) 1267
growth, GH and IGF- 1 therapy (abst) 1275
Helicobacter Pylon, HD (abst) 283
low protein-normal Na diet 852
luteinizing hormone, pubertal patients 1465
lysosomal iron accumulation (abst) 1268
mild, oral calcium suppresses PTH (abst) 1275
mild, serum and urinary ET-l (abst) 1274
muscle protein turnover 1432
non-diabetic, prevention of progression 45:S-167
plasma cytokines and inhibitors 890
PTH/PTHrP receptor down-regulation 605
renin-angiotensin system 403
Circadian blood pressure, monitoring, post-transplant
(abst) 1791
Circulatory investigations, HD (abst) 1788
Cirrhosis
acute saline loading response (abst) 1276
vasoactive intestinal peptide antagonist (abst) 1261
Cl channels, basolateral renal medullary vesicles 803
Clusterin depletion
experimental nephritis 817
perfused plasma, immune glomerular injury (abst).... 1278
Clusterin expression in human renal diseases 828
Cognitive functions, PTH, HD (abst) 291
COL4A5 gene deletion, Alport syndrome 721
Collagen
gene expression, MC growth 475
polyol pathway mediates synthesis, DM 659
Collagen type IV
Alport syndrome 721, 1504
distribution in IDDM 425
enalapril reduces synthesis 1637
Collagen type VI, diabetic glomeruli 1648
Collagenase type IV, MC synthesis (abst) 1782
Collapsing glomerulopathy 1416
Collecting ducts
Ca mediated hypertonicity, urea transport (abst) 1254
octopal cells, EGF, TGF-a 1510
Colony stimulating factor-i, lupus nephritis 45:S-83
Complement activation
mAb 254 detects neoepitope on C9 (abst) 1266
proximal tubular epithelial cells 451
Congenital nephrotic syndrome, Finnish type 986
Continuous ambulatory pentoneal dialysis (CAPD)
children, bone disease biochemical markers 253
glucose oxidation, pentoneal/oral glucose load 1147
heme biosynthesis, uremia 220
insufficient vitamin Bi and B6 (abst) 1786
lipid profile (abst) 291
normalized PCR as nutrition marker 103
patient mortality 1163
peritoneal access (abst) 287
peritoneal transport study 1738
Continuous veno-venous hemofiltration (abst) 1784
Coronary angiography, post-transplant (abst) 1258
Cortical collecting duct
Ca2 response, luminal vasopressin 811
metabolic support of Na transport 743
Cortical distal tubule, acidification 1543
Creatinine
serum, GFR recovery after CsA (abst) 1787
serum, renal EGF, dichromate effect 1622
Crescentic glomerulonephritis
delayed type hypersensitivity (abst) 1260
multinucleated giant cells (abst) 1260
Cryoglobulinemia, ARF, interferon a2a (abst) 1790
Cryoglobulins, IgG3 anti-TNP monoclonal,
glomerulopathy 962
Cuprophan membranes increase phospholipase A2
(abst) 1788
Cyclooxygenase 2, IL- 1, CsA, rat MC 150
Cyclophilin localization in the kidney 1340
Cyclophosphamide, lupus nephritis, children (abst) 289
Cyclosporin
BQ-123 effects, renal dysfunction 131
compared to prednisolone, azathiopnne (abst) 1264
renal functional reserve, transplantation 1657
steroid dependent nephrotic syndrome (abst) 1267
Cyclosporin A
GFR, hyperuricemia (abst) 1792
GFR recovery, serum creatinine (abst) 1787
inhibits IL-i-induced COX2 expression 150
long-term benefits/risks (abst) 1792
long-term renal tolerance 1446
nephrotoxicity, dopamine excretion (abst) 290
pharmacokinetics, compared CsG 684
Cyclosporine
induces antidiuresis 1203
induction therapy, transplantation (abst) 288
modulation of endothelin 592
pharmacokinetics, pre-transpiant (abst) 286
pharmacology, glomerular function 417
Cystic disease, renal, ACE inhibition (abst) 1266
Cystinosis, diagnosis (abst) 1269
Cystitis, women, lomefloxacin, trimethopnm (abst) 1267
Cytokines
autoantibodies, CRF 1484
immunopotentiation by RBC, anemia, uremia 224
induce leukemia inhibitory factor, MC 1562
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induction in high-flux HD (abst) 291
inhibit mesangial cell proliferation 159
specific inhibitors, CRF, CAPD, HD 890
Cytosolic calcium
altered homeostasis, cardiac monocytes, CRF 1113
protein kinases, hsp7O gene induction 1093
D
de Wardener, Hugh E 44:S-114, 44:S-115
Decidual capillary endothelial cells (abst) 1278
Deferoxamine therapy, Rhizopus pathogenicity 667
Dementia of HD, PTH, cognitive functions (abst) 291
Deoxyspergualin
does not inhibit monokine induction (abst) 1257
effects, rat MC (abst) 1271
suppresses adhesion molecule expression (abst) 1257
suppresses ICAM- 1, GN (abst) 1272
Desferrioxamine, reduces tubular damage (abst) 1277
Diabetes
ACE in kidneys, hypertension (abst) 1268
ambulatory BP, albuminuria 45:S-134
elevated collagen VI in glomeruli 1648
fish oil supplements, renal function (abst) 287
LDL influence, glomerular prostaglandins (abst) 1258
microalbuminuria, antihypertensive agents (abst) 1270
renal function, uninephrectomy (abst) 287
youth-onset, juxtaglomerular body abnormalities 1132
Diabetes mellitus
ACE inhibition, nephropathy 45:S-161
glomerular distribution, type IV collagen 425
glycine betaine, sorbitol, CRF (abst) 1267
radiocontrast nephropathy 259
regulation, vasopressin receptors (abst) 1275
thromboxane A2 inhibition, renal hemodynamics 794
Diabetic nephropathy
ACE inhibition 45:S-156, 45:S-161
clinical experience, treatment 45:S-l65
enalapril, long-term treatment 45:S-141
glomerular Ang II receptors (abst) 1276
hypercholesterolemia, renal function 45:S-125
localization ECM components (abst) 1271
monoclonal antibody treatment 1673
pathogenesis, blood viscosity (abst) 1273
polyol pathway, collagen synthesis 659
predisposition to 434
progression, assessment 45:S-121
progression, reduced albuminuria 45:S-l45
proximal tubular iron (abst) 1271
structural, functional correlations, Nephrology
Forum 612
Dialysate, low calcium, PTH rise (abst) 1253
Dialysis
disequilibrium syndrome 629
immunological considerations, uremia 44:S-92
metastatic endophthalmitis (abst) 1262
mortality, dysautonomia predicts (abst) 1274
mortality, high-flux, hypotension (abst) 1789
neutropenia, neutrophil F-actin (abst) 1253
peritoneal, Nephrology Forum 1226
plasmapheresis, plasma flux (abst) 289
PTH, molecule assays (abst) 1262
thrombolysis, thrombosed access grafts 1401
Dialyzer
clearance measurement accuracy, HD, K tlv (abst)... 1785
manual reprocessing, peracetic acid (abst) 1262
reuse system, evaluation (abst) 1788
Diastolic dysfunction, ventricular hypertrophy, EPO ... 1275
Dichromate, serum creatinine, renal EGF 1622
Dietary
fiber, idiopathic calcium nephrolithiasis (abst) 1782
fish oil, DM, renal function (abst) 287
protein, glomerular gene expression 1593
protein, low, adaptation, RF 1182
protein, low, normal Na in CRF 852
protein, serum calcitriol, calcium stones (abst) 1784
protein, tubular iron 1006
protein, tubular iron (abst) 1255
protein, uninephrectomy, ACE 1587
Dimercaptosuccinic acid scan, pyelonephritis (abst) .... 1790
Distal human tubular cells, characterization 85
Diuresis
natriuresis with EGF (abst) 1276
osmotic, before Homer W. Smith 1241
Diuretics, loop, hypoxic damage, proximal tubules 981
DNA
histone, DNA-anti-DNA immune complex 991
oxidant-induced injury, pyruvate 166
Donors, transplant, eligibility of elderly (abst) 1265
Dopamine
pharmacology, glomerular function 417
urinary excretion, CsA nephrotoxicity (abst) 290
Duodenal J chain expression in IgAN 836
Dysautonomia, predicts dialysis mortality (abst) 1274
E
Efferent arterioles, glomerular PGs, vascular activity.... 650
Eicosanoid biosynthesis and leukocyte adhesion 45:S-90
Elastase, GBM degradation, ROS, neutrophils 1555
Elderly as eligible transplant donors (abst) 1265
Electrolytes, tubular fluid, absorption analysis 1211
ELISA, anti-neutrophil proteinase 3 antibodies (abst)... 1257
Enalapril
long-term treatment, diabetic nephropathy 45:S-l41
reduces interstitial fibrosis 1637
renal effects in hypertensive IDDM 45:S-150
End-stage renal disease (ESRD)
calcitriol, bone mineral density 245
calcitriol, hyperparathyroidism 1710
EPO therapy, lipid profile 897
EPO therapy, lipid profile (abst) 1253
incidence, cumulative rates (abst) 1268
socioeconomic status, United States 907
sotalol and (abst) 1268
vocational rehabilitation, HD (abst) 1792
Endophthalmitis, metastatic, HD (abst) 1262
Endothelial cells
biology, glomerular 314
decidual capillary, pregnancy (abst) 1278
glomerular injury 45:S-37
glomerular injury, lipopolysaccharide (abst) 1783
IGF- 1 induces NO production 598
Endothelin
renal actions in disease 336
urine, HD, transplantation (abst) 1787
urine, normal/hypertensive pregnancy (abst) 1270
Endothelin- 1 (ET- 1)
endotoxin, glomerular hemodynamic resistance
(abst) 1783
gene expression, pre-eclamptic placenta (abst) 1265
heparin inhibits, mesangial cells 137
hypoxemia, renal dysfunction (abst) 1788
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urinary and serum, mild CRF (abst) 1274
urinary excretion, essential hypertension 556
Endothelin site selective modulation, cyclosporine 592
Endotoxin, glomerular resistance (abst) 1783
Endpoints
in non-diabetic patients 45:S-1 18
in progressive renal disease 45:S-132
Energy metabolism, renal mass reduction 45:S-i00
Epidermal growth factor (EGF)
antagonizes AVP 1028
anti-Thy-i nephritis (abst) 1272
arginine vasopressin (abst) 1262
detection in GS (abst) 1256
diuresis and natriuresis (abst) 1276
renal, dichromate, RF, thyroid hormone 1622
renal adenocarcinoma, retinoic acid 23
TGF-a, in human kidney 1510
Epithelial cells
cultured renal, fluid secretion 1369
escape from TGF-/31 642
glomerular disease 300
glomerular disease, progressive 45:S-58
Erythrocyte complement receptors, nephritis 493
Erythropoietin (EPO)
hepatitis B prophylaxis, HD (abst) 289
hypertension, calcium, uremia (abst) 1268
hypertension, NO pathway, uremia (abst) 1266
lipid profile, ESRD 897
lipid profile, ESRD (abst) 1253
promise/facts 44:S-70
subcutaneous, once/twice weekly, HD (abst) 1263
subcutaneous, pharmacokinetics, dosage (abst) 1263
subcutaneous/intravenous efficacy, HD (abst) 284
ventricular hypertrophy, diastolic dysfunction (abst).. 1275
Essential amino acids, ketoacids, protein intake, RF ... 1182
Essential hypertension
antihypertensive agents, microalbuminuria 45:S-17 1
intracellular Ca, Na/H exchanger 1037
Exercise-induced reduction RBF, indomethacin (abst) .. 1270
Extracapillary proliferative glomerulonephritis, ANCA-
positive (abst) 1790
Extracellular matrix
accumulation, tubulointerstitial injury 1077
diabetic nephropathy (abst) 1271
expansion, glomerular disease 45:S-45
glomerular 328
Extracellular volume, expanded, uridine metabolism
(abst) 1265
F
Familial amyloidotic polyneuropathy (abst) 287
Familial factors, diabetic nephropathy 434
Fea R expression, PMNL, superoxide generation,
IgAN 868
Ferrioxamine kinetics 76
Fiber, dietary, calcium nephrolithiasis (abst) 1782
Fibronectin biosynthesis, Ang II, At1 receptors 177
Fine-needle aspiration biopsy
cell proliferation, post-transplant (abst) 285
subcutaneous fat, nephropathology diagnosis (abst).... 284
Finnish type congenital nephrotic syndrome 986
Fish oil, renal function, diabetes (abst) 287
FK506 inhibits rat glomerular thrombosis 1572
Fluid
deprivation, osmoprotectant response (abst) 1277
secretion, cultured renal epithelium 1369
Focal glomerulosclerosis
gene expression, low protein diet 1593
segmental, collapsing glomerulopathy 1416
segmental, single nephron model 143
Folate supplementation, maintenance HD (abst) 1263
Fractional shortening, cardiac evaluation, HD (abst) .... 285
Friend erythroleukemia cells, Al, Fe metabolism 636
G
Galloway-Mowat syndrome 1407
Gangliosides expression, developing/adult kidney 123
Gene expression
focal GS, low protein diet 1593
glomerulosclerosis 45:S-48
Gene transfer
adenoviral-mediated, renal tubular cells 1220
metalloproteinase transin into MC 1580
Genetics
congenital nephrotic syndrome, Finnish 986
hypertension 44:S-57
Giebisch, Gerhard 44:S-106, 44:S-1i0
Glomerular basement membrane
degradation, ROS, elastase, neutrophils 1555
distension, podocytes counteract 369
minimal change disease (abst) 1256
Glomerular cells
glucocorticoid-induced Mn-SOD 211
lipopolysaccharide, EC injury, MC contraction (abst). 1783
in vitro versus in vivo 360
Glomerular deposition, DNA-anti-DNA immune
complex, histone 991
Glomerular disease
extracellular matrix and MC expansion 45:S-45
podocyte dysfunction 300
progressive, epithelial cell injury 45:S-58
Glomerular distribution, type IV collagen, IDDM 425
Glomerular epithelial cells
injury, glomerulosclerosis 45:S-58
urokinase-plasminogen activator synthesis 43
Glomerular expansion and mesangial cell strain 45:S-l 1
Glomerular extracellular matrix 328
Glomerular filtration rate
cyclosporin A, hyperuricemia (abst) 1792
long-term decline, antiproteinuric response 45:S-174
recovery after CsA, plasma creatinine (abst) 1787
reduction, contrast media, theophylline 1425
renal functional reserve 411
Glomerular function
endothelin, renal actions in disease 336
loss of, tubulointerstitial fibrosis 345
modulated by ACE inhibition, PAN 537
pharmacologic manipulation 417
renin-angiotensin system, CRF 403
single nephron studies, human 384
Glomerular gangliosides 123
Glomerular gene expression, dietary protein, focal GS.. 1593
Glomerular hemodynamic resistance, endotoxin (abst).. 1783
Glomerular hypertension
progression, versus systemic 438
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cellular mechanisms, metabolic factors . . . 45:S-54, 45:S-56
clusterin depletion, perfused plasma 817
clusterin depletion, perfused plasma (abst) 1278
inflammation, macrophages in 945
leukocyte adhesion molecules 45:S-98
macrophages, role of 45:S-98
oxidants and proteases 352
proinflammatory mediators, T cell activation 44:S-8
promoted by MC oxidation of LDL 1628
response to, Nephrology Forum 1768
tumor necrosis factor alpha 45:S-32
vascular endothelial cell activation 45:S-37
Glomerular leukocytic accumulation, ICAM- l/LFA- 1,
anti-GEM GN 700
Glomerular macrophage phagocytosis 1326
Glomerular number from MRI and biopsy 1668
Glomerular permeability 398
Glomerular prostaglandins
afferent and efferent arterioles 650
production, lipoproteins, DM (abst) 1258
Glomerular sclerosis, podocyte role 45:S-64
Glomerular thrombosis
FKSO6, nephrotoxic serum, lipopolysaccharide 1572
NO role, pregnancy 775
Glomeruli
biology of, endothelial cells 314
diabetic, elevated collagen VI 1648
normallpathologic, tenascin 201
normal/sclerotic, mesangial matrix 45:S-73
Glomerulonephritis
ANCA-positive (abst) 1790
anti-GBM, /32 integrin, glomerular neutrophils (abst).. 1256
anti-GBM, ICAM-i 32
anti-GBM, ICAM-1/LFA-1 interaction 700
anti-GBM, T helper/suppressor cells (abst) 1260
attenuated by 5-LO inhibition 1301
crescentic (abst) 1260
deoxyspergualin suppresses ICAM-1 (abst) 1272
IL-6 exacerbates (abst) 1787
immune complex, erythrocyte CR! 493
immune complex, NO-synthase induced, rat 1215




IgG3 anti-TNP monoclonal cryoglobulins 962
minimal change, with bronchiolitis
obliterans/organizing pneumonia (abst) 1790
progressive, glomerular hypertrophy and 45:S-27
Glomeruloscierosis
adriamycin nephropathy, TGF-f31 525
epidermal growth factor (abst) 1256
epithelial cell injury 45: S-58
focal, glomerular gene expression, low protein diet... 1593
focal segmental, collapsing glomerulopathy 1416




Glucose oxidation in dialyzed patients 1147
Glycated albumin, diabetic nephropathy 1673
Glycine betaine
urine, aminoglycosides (abst) 1256
urine and blood levels, human (abst) 1275
urine levels, sorbitol, DM, CRF (abst) 1267
Growth, body
catch-up, children, renal tubular acidosis (abst) 1782
IGF- 1, renal function, ARF (abst) 1277
Growth factors
autocrine for MC in vitro, IL-i (abst) 1257
epidermal, interaction, AVP (abst) 1262
hypertrophy/hyperplasia, proximal tubular epithelium
(abst) 1261
internephron heterogeneity, sclerosis 45:S-24
Growth hormone
gene activation, glomerulosclerosis 45:S-48
receptor expression, uremia 1085
therapy, short children, CRF (abst) 1273
therapy, with IGF- 1, CRF (abst) 1275
Guanidino, NO synthase inhibition, uremic toxins 737
H
H4 cells, albumin and transferrin synthesis 1381
Haemorheology
altered, pathogenesis of diabetic nephropathy (abst) .. 1273
changes in IgA nephropathy (abst) 1266
Hamburger Award, 1993 44:S-l12, 44:S-l13, 44:S-l14,
44:S-115
Hantavirus disease, hemorragic fever, renal syndrome
(abst) 291
Heart transplantation, simultaneous with kidney (abst).. 1254
Helicobacter Pylon infection, chronic HD (abst) 283
Hematuria, macroscopic after renal biopsy (abst) 286
Heme biosynthesis in uremia 220
Hemodialysis
acetate vs. bicarbonate (abst) 1784
AN69 membranes, bradykinin mediates anaphylaxis.. 1497
anemia, intravenous iron (abst) 285
anticoagulation control 912
blood volume measurements, noninvasive (abst) 1262
calcitriol, bone mineral density (abst) 1786
calcitriol, high dose oral, children, (abst) 1264
carpal tunnel syndrome (abst) 284
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iron load, HD (abst) 289
prophylaxis, HD (abst) 289
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Hypofiltration, glomerular, membranous nephropathy ... 390
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cryoglobulins, IgG3 anti-TNP, glomerulopathy 962
marker, Alport syndrome, type IV collagen 1504
Monoclonal antibody therapy
diabetic nephropathy 1673
Heymann's nephritis (abst) 1272
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diabetic, long-term enalapril 45:S-141
diabetic, monoclonal antibody treatment 1673
diabetic, Nephrology Forum 612
diabetic, pathogenesis (abst) 1273
diabetic, predisposition 434
diabetic, proximal tubular iron (abst) 1271
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I ,25(OH)2D3, calbindin D-28K, bovine renal cells 95
OKT3
reduced viral mortality (abst) 1265
single transplant experience (abst) 1264
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